Tender Details

Country: USA
Summary: Integrating Biospecimen Science Approaches into Clinical Assay Development (U01 Clinical Trial Not Allowed)
UST Ref No: 27212933
Deadline: 11 Jul 2021
Financier: Self Financed
Purchaser Ownership: Government
Tender Value: Refer Document
Notice Type: Tender
Document Ref. No.: PAR-18-947
Purchaser's Detail:
Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details.
Login to see details
Description:
Tender are invited for Integrating Biospecimen Science Approaches into Clinical Assay Development (U01 Clinical Trial Not Allowed)
CFDA Number : 93.393 -- Cancer Cause and Prevention Research93.394 -- Cancer Detection and Diagnosis Research
Cost Sharing or Matching Requirement : No
Closing Date for Applications: Jul 11, 2021
Posted Date : Sep 28, 2018
Description: This Funding Opportunity Announcement (FOA) will support extramural research to investigate and mitigate challenges facing clinical assay development and subsequent analytical validation due to preanalytical variability in tumor tissue biopsies and blood biospecimens utilized as liquid biopsies. Extramural research funded under this FOA may include investigations of preanalytical variability relevant to diagnostic associated with the procurement and study of small biopsies (core biopsies, small excision samples), pleural aspirates, and blood utilized for liquid biopsies. Investigator-designed experiments will explore how different biospecimen preanalytical conditions affect emerging and clinically relevant biomarkers quantified by a variety of testing platforms. The results from this research program will improve the understanding of how analytical quantification of clinically relevant biomarkers is affected by variation in biospecimen collection, processing, and storage procedures. The overall goal is to expedite biomarker clinical assay development through evidence-based standardization of biopsy handling practices.
Documents:

If you are registered member, kindly login to view full details of this tender notice:

Integrating Biospecimen Science Approaches into Clinical Assay Development (U01 Clinical Trial Not Allowed) - USA Tender

The NATIONAL INSTITUTES OF HEALTH, a Government sector organization in USA, has announced a new tender for Integrating Biospecimen Science Approaches into Clinical Assay Development (U01 Clinical Trial Not Allowed). This tender is published on USARFP under UST Ref No: 27212933 and is categorized as a Tender. Interested and eligible suppliers are invited to participate by reviewing the tender documents and submitting their bids before the deadline on 2021-07-11.

The estimated tender value is Refer Document, and full details, including technical specifications and submission requirements, are provided in the official tender documents. Ensure all submissions meet the criteria outlined to be considered for evaluation.